K
Kezar Life Sciences, Inc. (KZR)
NCM – Real Time Price. Currency in USD
7.29
0.00 (0.00%)
At close: May 8, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
7.29
0.00 (0.00%)
At close: May 8, 2026, 4:00 PM EDT
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, CEO & Director |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Mr. John Franklin Fowler | Co-Founder & Director |
| Mr. Mark Schiller | Chief Operations Officer |
| Ms. Pichi Chiang | Senior Vice President & Controller |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 10-K/A | kzr-20251231.htm |
| 2026-04-14 | SC 14D9 | ny20070329x1_sc14d9.htm |
| 2026-04-13 | SC TO-T | ny20070168x1_sctot.htm |
| 2026-04-03 | 8-K | kzr-20260401.htm |
| 2026-03-30 | SC14D9C | d280757dsc14d9c.htm |
| 2026-03-27 | 10-K | kzr-20251231.htm |
| 2026-03-12 | 8-K | kzr-20260306.htm |
| 2025-11-12 | 8-K | kzr-20251112.htm |
| 2025-11-07 | 8-K | kzr-20251106.htm |
| 2025-10-22 | 8-K | kzr-20251020.htm |